AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18434299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation with complete slow pathway block
Number of subjects: 160
Study 18434299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation with incomplete slow pathway block
Number of subjects: 160
Study 18434299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation with atrial echo beats present
Number of subjects: 160
Study 18434299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 160
Study 22169408 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Number of subjects: 66
Study 22169408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15673460 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption; specific dosage and duration not mentioned.
Number of subjects: 0
Study 15673460 — intervention group
Group type: COMPARATOR
Intervention: Nicotine consumption; specific dosage and duration not mentioned.
Number of subjects: 0
Study 15673460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention); specific details not mentioned.
Number of subjects: 0
Study 12359687 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine augmentation for 8 weeks
Number of subjects: 19
Study 12359687 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration for 8 weeks
Number of subjects: 19
Study 9615879 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% pure ethanol solution
Number of subjects: 47
Study 9615879 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% pure ethanol solution
Number of subjects: 47
Study 9615879 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% pure ethanol solution
Number of subjects: 47
Study 9615879 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 47
Study 9615879 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 47
Study 9615879 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine
Number of subjects: 47
Study 9615879 — intervention group
Group type: EXPERIMENTAL
Intervention: Whisky
Number of subjects: 47
Study 9615879 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 47
Study 8575493 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchidectomy plus cyproterone acetate 50 mg 3 times a day
Number of subjects: 328
Study 8575493 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol 1 mg daily
Number of subjects: 328
Study 8575493 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 328
Study 2917112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 0.6 MAC
Number of subjects: 8
Study 2917112 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane at 0.6 MAC
Number of subjects: 8
Study 1181361 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 23
Study 1181361 — intervention group
Group type: EXPERIMENTAL
Intervention: Social group
Number of subjects: 23
Study 1181361 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 29788732 — intervention group
Group type: EXPERIMENTAL
Intervention: SLN intra‐operative histopathological assessment
Number of subjects: 1284
Study 29788732 — intervention group
Group type: COMPARATOR
Intervention: No routine SLN intra‐operative histopathological evaluation
Number of subjects: 1284
Study 28417835 — intervention group
Group type: EXPERIMENTAL
Intervention: EANx
Number of subjects: 8
Study 28417835 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 8
Study 25115966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602
Study 25115966 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 3602
Study 25115966 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 3602
Study 23460714 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus gefitinib 250 mg/d, orally (arm B)
Number of subjects: 270
Study 23460714 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus placebo (arm A)
Number of subjects: 270
Study 23460714 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus gefitinib (arm B)
Number of subjects: 270
Study 23460714 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib after disease progression in arm A
Number of subjects: 270
Study 22186854 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate mouthwash
Number of subjects: 100
Study 22186854 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric mouthwash
Number of subjects: 100
Study 19081898 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaStyle Paint On Plus (Ivoclar Vivadent)
Number of subjects: 10
Study 16140283 — intervention group
Group type: COMPARATOR
Intervention: Acute ketamine (two doses)
Number of subjects: 80
Study 16140283 — intervention group
Group type: COMPARATOR
Intervention: Chronic ketamine use
Number of subjects: 80
Study 12672917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pullulan
Number of subjects: 28
Study 12672917 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 28
Study 10941967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk (1.0 g/dL cow's milk fat)
Number of subjects: 38
Study 10941967 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially vegetable fat milk (3.5 g/dL fat; 50% vegetable fat: rapeseed oil)
Number of subjects: 38
Study 10941967 — intervention group
Group type: EXPERIMENTAL
Intervention: Full vegetable-fat milk (3.5 g/dL fat; 100% vegetable fat: palm, coconut, and soy oil)
Number of subjects: 38
Study 10941967 — intervention group
Group type: COMPARATOR
Intervention: Standard-fat milk (3.5 g/dL cow's milk fat)
Number of subjects: 38
Study 9219147 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg/day
Number of subjects: 32
Study 9219147 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 10 mg/day (control)
Number of subjects: 32
Study 1350868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined neural and hormonal blockade (somatostatin and etomidate with thoracic epidural analgesia)
Number of subjects: 24
Study 1350868 — intervention group
Group type: COMPARATOR
Intervention: No blockade (control group)
Number of subjects: 24
Study 6431142 — intervention group
Group type: EXPERIMENTAL
Intervention: PS‐K
Number of subjects: 435
Study 6431142 — intervention group
Group type: EXPERIMENTAL
Intervention: FT‐207
Number of subjects: 435
Study 6431142 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 435
Study 6431142 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐vitro lymphocyte responsiveness study
Number of subjects: 435
Study 6431142 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunofluorescent study
Number of subjects: 435
Study 29309951 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participant-observer group (AP-O group)
Number of subjects: 104
Study 29309951 — intervention group
Group type: COMPARATOR
Intervention: Observer group (O group)
Number of subjects: 104
Study 29309951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 28007201 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PCI
Number of subjects: 1800
Study 28007201 — intervention group
Group type: COMPARATOR
Intervention: Initial CABG
Number of subjects: 1800
Study 28007201 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat revascularization after initial PCI
Number of subjects: 1800
Study 28007201 — intervention group
Group type: COMPARATOR
Intervention: Repeat revascularization after initial CABG
Number of subjects: 1800
Study 25632806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium (50 mg, 3 times/day)
Number of subjects: 427
Study 25632806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times/day)
Number of subjects: 427
Study 22943846 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 18
Study 22943846 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 18
Study 20638563 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 4484
Study 20638563 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac slow release 75 mg twice a day plus omeprazole 20 mg once a day
Number of subjects: 4484
Study 17662503 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic dieting for 4 weeks
Number of subjects: 157
Study 17662503 — intervention group
Group type: COMPARATOR
Intervention: Control group (eat as they normally do when not dieting)
Number of subjects: 157
Study 16344218 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18% isotretinoin
Number of subjects: 70
Study 16344218 — intervention group
Group type: COMPARATOR
Intervention: 0.05% isotretinoin
Number of subjects: 70
Study 15116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Red carrots (5 mg/day)
Number of subjects: 19
Study 15116084 — intervention group
Group type: COMPARATOR
Intervention: Tomato paste (20 mg/day)
Number of subjects: 19
Study 15116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Red carrots (2.6 mg/day)
Number of subjects: 19
Study 15116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato paste (5 mg/day)
Number of subjects: 19
Study 15116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato paste plus white carrots (5 mg/day)
Number of subjects: 19
Study 15116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed dietary sources of lycopene (2 mg/day)
Number of subjects: 19
Study 15116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed dietary sources of lycopene (>/=20 mg/day)
Number of subjects: 19
Study 15116084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene from red carrots
Number of subjects: 19
Study 11297716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention designed to reduce anxiety/distress responses to the doxapram injection
Number of subjects: 16
Study 11297716 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram-induced hyperventilation
Number of subjects: 16
Study 11297716 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study 11297716 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic patients
Number of subjects: 16
Study 9142004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT) during lower-body negative pressure (LBNP)
Number of subjects: 22
Study 9142004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT) during hemodialysis
Number of subjects: 22
Study 9142004 — intervention group
Group type: COMPARATOR
Intervention: Lower-body negative pressure (LBNP) alone
Number of subjects: 22
Study 7971299 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 2 digital test
Number of subjects: 208
Study 3499486 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz TENS
Number of subjects: 40
Study 3499486 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz TENS
Number of subjects: 40
Study 3499486 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz vibration
Number of subjects: 40
Study 3499486 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 30317264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat phobia scale
Number of subjects: 2100
Study 30317264 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward obese persons scale
Number of subjects: 2100
Study 30317264 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between fat phobia scale, attitudes toward obese persons scale, and health‐promoting lifestyle profile II scale scores
Number of subjects: 2100
Study 26098271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficacy condition
Number of subjects: 44
Study 26098271 — intervention group
Group type: COMPARATOR
Intervention: Low-efficacy condition
Number of subjects: 44
Study 25359327 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (Xeno III)
Number of subjects: 78
Study 25359327 — intervention group
Group type: COMPARATOR
Intervention: Two-step etch-and-rinse adhesive (Excite)
Number of subjects: 78
Study 24164227 — intervention group
Group type: EXPERIMENTAL
Intervention: ASK (tobacco screening)
Number of subjects: 190
Study 24164227 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVISE (tobacco advising)
Number of subjects: 190
Study 24164227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use identification
Number of subjects: 190
Study 24164227 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations with ASK and ADVISE
Number of subjects: 190
Study 24164227 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice characteristics
Number of subjects: 190
Study 24164227 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of tobacco users in the practice
Number of subjects: 190
Study 20576390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous systemic administration of tPA within 4.5 hours
Number of subjects: 0
Study 20576390 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis within 4.5 hours
Number of subjects: 0
Study 20576390 — intervention group
Group type: COMPARATOR
Intervention: Control groups from ECASS II and ATLANTIS studies
Number of subjects: 0
Study 19202718 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-specific dance intervention, 2 times per week for 8 weeks
Number of subjects: 126
Study 19202718 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 126
Study 16595102 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive programme of secondary prevention
Number of subjects: 0
Study 16595102 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 12891263 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 10636365 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting with abciximab
Number of subjects: 2399
Study 10636365 — intervention group
Group type: COMPARATOR
Intervention: Stenting with placebo
Number of subjects: 2399
Study 10636365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint of death or large myocardial infarction for stenting with abciximab
Number of subjects: 2399
Study 10636365 — intervention group
Group type: COMPARATOR
Intervention: Combined endpoint of death or large myocardial infarction for stenting with placebo
Number of subjects: 2399
Study 10636365 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty with abciximab
Number of subjects: 2399
Study 10636365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of stenting plus abciximab
Number of subjects: 2399
Study 7793195 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 1.0‐4.5% and oxygen (n = 40)
Number of subjects: 80
Study 7793195 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide 30‐60% in oxygen (n = 40)
Number of subjects: 80
Study 1903918 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (0.15 mg.kg‐1.h‐1 after a loading dose of 2 mg.kg‐1)
Number of subjects: 30
Study 1903918 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (10 micrograms.kg‐1 for 12 hours, then 0.25 mg.24 h‐1)
Number of subjects: 30
Study 7030978 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxdralazine
Number of subjects: 31
Study 7030978 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 31
Study 31704050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-calcium supplementation
Number of subjects: 178
Study 31704050 — intervention group
Group type: COMPARATOR
Intervention: Non-vitamin D group
Number of subjects: 178
Study 30247967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Care Toolkit (SCT)
Number of subjects: 100
Study 30247967 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study 26945825 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 200
Study 26945825 — intervention group
Group type: COMPARATOR
Intervention: SPMC
Number of subjects: 200
Study 26363825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (25mg every 12h for 3 days and 600μg buccal misoprostol on the morning of the fourth day)
Number of subjects: 40
Study 26363825 — intervention group
Group type: COMPARATOR
Intervention: Control group (vacuum aspiration)
Number of subjects: 40
Study 23631765 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterintuitive concepts with one violation (Experiment 1)
Number of subjects: 0
Study 23631765 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterintuitive concepts with two violations (Experiment 2)
Number of subjects: 0
Study 23631765 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterintuitive concepts with three violations (Experiment 3)
Number of subjects: 0
Study 23631765 — intervention group
Group type: COMPARATOR
Intervention: Intuitive concepts
Number of subjects: 0
Study 20939675 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) plus clomiphene citrate (CC)
Number of subjects: 192
Study 20939675 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus clomiphene citrate (CC)
Number of subjects: 192
Study 18230694 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg daily for 7 days)
Number of subjects: 20
Study 18230694 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion
Number of subjects: 20
Study 16596921 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists with master's level postgraduate studies
Number of subjects: 18
Study 16596921 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists choosing not to refer patients due to concern for poor medical prognosis
Number of subjects: 18
Study 15163387 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril treatment group
Number of subjects: 58
Study 15163387 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment group
Number of subjects: 58
Study 10377639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfluoridated resin composite with fluoridated dentifrice
Number of subjects: 21
Study 10377639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated resin composite with fluoridated dentifrice
Number of subjects: 21
Study 10377639 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer restorative materials with fluoridated dentifrice
Number of subjects: 21
Study 10377639 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement with nonfluoridated dentifrice
Number of subjects: 21
Study 10377639 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated resin composite control with nonfluoridated dentifrice
Number of subjects: 21
Study 8933294 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme involving academic detailing by pharmacists to general practitioners in Southern Tasmania.
Number of subjects: 250
Study 8933294 — intervention group
Group type: COMPARATOR
Intervention: Control area (North of Tasmania) with no educational intervention.
Number of subjects: 250
Study 1753554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur plus tamoxifen
Number of subjects: 228
Study 1753554 — intervention group
Group type: COMPARATOR
Intervention: Tegafur alone
Number of subjects: 228
Study 6761890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (ASA + DPM)
Number of subjects: 27
Study 6761890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6761890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (ASA + DPM) post-operative therapy
Number of subjects: 27
Study 4011071 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone and early delivery
Number of subjects: 0
Study 4011071 — intervention group
Group type: EXPERIMENTAL
Intervention: Early delivery alone
Number of subjects: 0
Study 4011071 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 0
Study 29868695 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-facilitated debriefing
Number of subjects: 23
Study 29868695 — intervention group
Group type: EXPERIMENTAL
Intervention: Faculty-facilitated debriefing
Number of subjects: 23
Study 27231549 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug combination therapy (low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine)
Number of subjects: 0
Study 27231549 — intervention group
Group type: COMPARATOR
Intervention: Three-drug combination therapy (tacrolimus, mycophenolate mofetil, and corticosteroids)
Number of subjects: 0
Study 24067865 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, intensive WBV training
Number of subjects: 15
Study 24067865 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 15
Study 21678163 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood with strong arguments
Number of subjects: 127
Study 21678163 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood with weak arguments
Number of subjects: 127
Study 21678163 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood with strong arguments
Number of subjects: 127
Study 21678163 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood with weak arguments
Number of subjects: 127
Study 21678163 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 127
Study 21678163 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 127
Study 20211992 — intervention group
Group type: EXPERIMENTAL
Intervention: Living donors and general public (risk communication presentation)
Number of subjects: 151
Study 18522640 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (intervention group)
Number of subjects: 309
Study 18522640 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative endoscopy (QE) measurements
Number of subjects: 309
Study 18522640 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in surface area measurements over time
Number of subjects: 309
Study 18522640 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of Barrett's lesion type
Number of subjects: 309
Study 16045523 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 microg
Number of subjects: 126
Study 16045523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 12095381 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir
Number of subjects: 481